Financhill
Sell
34

TOVX Quote, Financials, Valuation and Earnings

Last price:
$1.50
Seasonality move :
-9.16%
Day range:
$1.40 - $1.53
52-week range:
$1.14 - $17.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.59x
P/B ratio:
0.16x
Volume:
81.3K
Avg. volume:
253.6K
1-year change:
-89.1%
Market cap:
$4M
Revenue:
--
EPS (TTM):
-$33.18

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% --
IBIO
iBio
-- -$0.46 -100% -62.35% $4.78
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 -60.77% -99.16% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- --
PTN
Palatin Technologies
-- -$0.42 -100% -25% $17.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TOVX
Theriva Biologics
$1.43 -- $4M -- $0.00 0% 1.59x
IBIO
iBio
$3.17 $4.78 $31.3M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.65 $0.85 $3.2M -- $0.00 0% 0.07x
NNVC
Nanoviricides
$1.33 -- $19.1M -- $0.00 0% --
OGEN
Oragenics
$0.27 -- $3.3M -- $0.00 0% 1.05x
PTN
Palatin Technologies
$0.99 $17.00 $23.2M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TOVX
Theriva Biologics
-- -1.924 -- --
IBIO
iBio
5.96% 8.122 3.92% 1.49x
NBY
NovaBay Pharmaceuticals
4.54% 0.531 1.51% 0.75x
NNVC
Nanoviricides
-- 2.048 -- --
OGEN
Oragenics
-- 2.260 -- --
PTN
Palatin Technologies
-- -3.039 -- 0.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TOVX
Theriva Biologics
-- -$5M -- -- -- -$3.9M
IBIO
iBio
-- -$4.4M -83.08% -110.9% -2153.5% -$3.9M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
NNVC
Nanoviricides
-- -$3.2M -- -- -- -$2.6M
OGEN
Oragenics
-- -$2.4M -- -- -- -$2M
PTN
Palatin Technologies
$350K -$7.8M -- -- -2356.3% -$7M

Theriva Biologics vs. Competitors

  • Which has Higher Returns TOVX or IBIO?

    iBio has a net margin of -- compared to Theriva Biologics's net margin of -2182%. Theriva Biologics's return on equity of -- beat iBio's return on equity of -110.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$6.81 --
    IBIO
    iBio
    -- -$0.48 $14.8M
  • What do Analysts Say About TOVX or IBIO?

    Theriva Biologics has a consensus price target of --, signalling upside risk potential of 6228.67%. On the other hand iBio has an analysts' consensus of $4.78 which suggests that it could grow by 50.79%. Given that Theriva Biologics has higher upside potential than iBio, analysts believe Theriva Biologics is more attractive than iBio.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    0 0 0
    IBIO
    iBio
    2 0 0
  • Is TOVX or IBIO More Risky?

    Theriva Biologics has a beta of 1.217, which suggesting that the stock is 21.656% more volatile than S&P 500. In comparison iBio has a beta of -3.256, suggesting its less volatile than the S&P 500 by 425.568%.

  • Which is a Better Dividend Stock TOVX or IBIO?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or IBIO?

    Theriva Biologics quarterly revenues are --, which are smaller than iBio quarterly revenues of $200K. Theriva Biologics's net income of -$7.7M is lower than iBio's net income of -$4.4M. Notably, Theriva Biologics's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 1.59x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    1.59x -- -- -$7.7M
    IBIO
    iBio
    -- -- $200K -$4.4M
  • Which has Higher Returns TOVX or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Theriva Biologics's net margin of -49.65%. Theriva Biologics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$6.81 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About TOVX or NBY?

    Theriva Biologics has a consensus price target of --, signalling upside risk potential of 6228.67%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that Theriva Biologics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Theriva Biologics is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    0 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is TOVX or NBY More Risky?

    Theriva Biologics has a beta of 1.217, which suggesting that the stock is 21.656% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.665, suggesting its less volatile than the S&P 500 by 33.493%.

  • Which is a Better Dividend Stock TOVX or NBY?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or NBY?

    Theriva Biologics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Theriva Biologics's net income of -$7.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Theriva Biologics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 1.59x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    1.59x -- -- -$7.7M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns TOVX or NNVC?

    Nanoviricides has a net margin of -- compared to Theriva Biologics's net margin of --. Theriva Biologics's return on equity of -- beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$6.81 --
    NNVC
    Nanoviricides
    -- -$0.23 --
  • What do Analysts Say About TOVX or NNVC?

    Theriva Biologics has a consensus price target of --, signalling upside risk potential of 6228.67%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 388.72%. Given that Theriva Biologics has higher upside potential than Nanoviricides, analysts believe Theriva Biologics is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    0 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is TOVX or NNVC More Risky?

    Theriva Biologics has a beta of 1.217, which suggesting that the stock is 21.656% more volatile than S&P 500. In comparison Nanoviricides has a beta of 1.349, suggesting its more volatile than the S&P 500 by 34.901%.

  • Which is a Better Dividend Stock TOVX or NNVC?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or NNVC?

    Theriva Biologics quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Theriva Biologics's net income of -$7.7M is lower than Nanoviricides's net income of -$3.1M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 1.59x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    1.59x -- -- -$7.7M
    NNVC
    Nanoviricides
    -- -- -- -$3.1M
  • Which has Higher Returns TOVX or OGEN?

    Oragenics has a net margin of -- compared to Theriva Biologics's net margin of --. Theriva Biologics's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$6.81 --
    OGEN
    Oragenics
    -- -$0.38 --
  • What do Analysts Say About TOVX or OGEN?

    Theriva Biologics has a consensus price target of --, signalling upside risk potential of 6228.67%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 33482.08%. Given that Oragenics has higher upside potential than Theriva Biologics, analysts believe Oragenics is more attractive than Theriva Biologics.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    0 0 0
    OGEN
    Oragenics
    0 0 0
  • Is TOVX or OGEN More Risky?

    Theriva Biologics has a beta of 1.217, which suggesting that the stock is 21.656% more volatile than S&P 500. In comparison Oragenics has a beta of 0.380, suggesting its less volatile than the S&P 500 by 62.042%.

  • Which is a Better Dividend Stock TOVX or OGEN?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or OGEN?

    Theriva Biologics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Theriva Biologics's net income of -$7.7M is lower than Oragenics's net income of -$2.5M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 1.59x versus 1.05x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    1.59x -- -- -$7.7M
    OGEN
    Oragenics
    1.05x -- -- -$2.5M
  • Which has Higher Returns TOVX or PTN?

    Palatin Technologies has a net margin of -- compared to Theriva Biologics's net margin of -2357.27%. Theriva Biologics's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$6.81 --
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
  • What do Analysts Say About TOVX or PTN?

    Theriva Biologics has a consensus price target of --, signalling upside risk potential of 6228.67%. On the other hand Palatin Technologies has an analysts' consensus of $17.00 which suggests that it could grow by 1617%. Given that Theriva Biologics has higher upside potential than Palatin Technologies, analysts believe Theriva Biologics is more attractive than Palatin Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    0 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is TOVX or PTN More Risky?

    Theriva Biologics has a beta of 1.217, which suggesting that the stock is 21.656% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.651%.

  • Which is a Better Dividend Stock TOVX or PTN?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or PTN?

    Theriva Biologics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Theriva Biologics's net income of -$7.7M is higher than Palatin Technologies's net income of -$7.8M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 1.59x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    1.59x -- -- -$7.7M
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 111x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
65
ATEX alert for Feb 12

Anterix [ATEX] is down 0.72% over the past day.

Buy
87
GDS alert for Feb 12

GDS Holdings [GDS] is up 0.32% over the past day.

Sell
30
SPSC alert for Feb 12

SPS Commerce [SPSC] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock